Avalo Therapeutics Inc. (AVTX) PT Lowered to $55 at Citizens, Reflecting Recent Equity Financing

Citizens analyst Jason Butler lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $55.00 (from $62.00) while maintaining a Market Outperform rating.

The analyst commented, "Positive Phase 2 LOTUS results support advancement to registrational studies; we reiterate our Market Outperform rating on Avalo Therapeutics though lower our risk-adjusted, DCFderived price target to $55 from $62 to reflect the recent equity financing. This morning, Avalo reported 1Q26 financial results and business updates, underscoring its plans to advance abdakibart into registrational Phase 3 studies. Recall, the Phase 2 LOTUS trial demonstrated positive results (our note here) with, in our view, a robust and competitive magnitude of benefit. The company ended 1Q26 with $82MM in cash, and raised net proceeds of ~ $40MM from the equity offering that followed the announcement of Phase 2 results."

You May Also Be Interested In

• Birkenstock Holding plc (BIRK) PT Raised to $44 at Morgan Stanley
• Veritone (VERI) Misses Q2 EPS by 13c ; Offers Guidance
• York Space Systems, Inc. (YSS) Reports Q2 Loss of $0.31 ; Offers Guidance